BioPhy, a company that helps enhance the outcomes of clinical trials, raised $4.5 million in pre-seed funding, CEO Dave Latshaw II tells Axios exclusively.
Why it matters: Clinical trials have only a 7.9% success rate, limiting the chances of curing, preventing, or earlier diagnosis of serious and deadly diseases.
/2023/11/06/1699306485296.gif?w=3840)
